Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer Split, Once Decided, Could Happen Quickly, CEO Says

Executive Summary

Pfizer Inc. could complete a business breakup in about one year if the company decides to move forward with a split, CEO Ian Read said during the company’s first quarter sales and earnings call May 3.

You may also be interested in...

Stockwatch: Big Pharma Strikes Back In Earnings War

After a phony first week for first-quarter earnings season, the second week was one of missed estimates and reduced guidance at big biotech companies. Last week – the third week – was different again, with big pharmaceutical companies restoring some honor to the life sciences sector.

White House, Allergan Spar Over 'Un-American' Claim

The White House on April 6 fought back against accusations from Allergan PLC CEO Brent Saunders the Obama administration's move to institute new rules aimed at thwarting corporate inversion was "un-American" and had specifically been constructed to take down the company's $160bn merger deal with Pfizer Inc., which had, indeed, fallen apart in light of the US Treasury Department's actions.

Pfizer-Allergan Merger: The End Is Nigh

The end of Pfizer Inc.'s $160bn merger with Allergan PLC was nearly official late on April 5 after the US Treasury Department issued new rules endorsed by President Barack Obama to prevent tax inversion deals, leading analysts and industry observers to declare the "PfizerGan" transaction unlikely.

Related Content


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts